The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin
暂无分享,去创建一个
A. V. van Herwaarden | A. Schinkel | J. Jonker | E. Wagenaar | G. Merino | Alfred H Schinkel | Els Wagenaar | Gracia Merino | Johan W Jonker | Antonius E van Herwaarden
[1] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[2] H. Kusuhara,et al. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[3] I. Schoots,et al. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. , 2001, Molecular pharmacology.
[4] R. C. Bender,et al. Studies on the distribution and excretion of certain nitrofurans. , 1960, Antibiotics & chemotherapy.
[5] M. Neville,et al. Active transport of nitrofurantoin across the mammary epithelium in vivo. , 1997, The Journal of pharmacology and experimental therapeutics.
[6] Jos H Beijnen,et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.
[7] Y. Sugiyama,et al. Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.
[8] S. Cisternino,et al. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. , 2004, Cancer research.
[9] M. Neville,et al. Active transport of nitrofurantoin across a mouse mammary epithelial monolayer. , 1997, The Journal of pharmacology and experimental therapeutics.
[10] M. Kool,et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.
[11] P. McNamara,et al. Active Transport of Nitrofurantoin into Human Milk , 2001, Pharmacotherapy.
[12] A. V. Van Gennip,et al. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. , 2001, Carcinogenesis.
[13] Improved LC method to determine ivermectin in plasma. , 2003, Journal of pharmaceutical and biomedical analysis.
[14] J. Schellens,et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.
[15] P. McNamara,et al. Basolateral active uptake of nitrofurantoin in the CIT3 cell culture model of lactation. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[16] P. McNamara,et al. Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk. , 2001, The Journal of pharmacology and experimental therapeutics.
[17] Alfred H. Schinkel,et al. Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.
[18] T. Dale,et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk , 2005, Nature Medicine.
[19] J. Møller,et al. Renal organic anion transport system: pharmacological, physiological, and biochemical aspects. , 1982, Pharmacological reviews.
[20] Sharon Marsh,et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype , 2004, Clinical pharmacology and therapeutics.
[21] J. D. Conklin,et al. Studies on the absorption, distribution and elimination of nitrofurantoin in the rat. , 1961, The Journal of pharmacology and experimental therapeutics.
[22] W. El-Deiry. Phenomenology and Scientific Progress , 2002, Cancer biology & therapy.
[23] A. Pardee. Role Reversal for Anticancer Agents , 2002, Cancer biology & therapy.
[24] J. Beijnen,et al. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. , 2001, Molecular pharmacology.
[25] A. Schinkel,et al. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). , 2002, Molecular cancer therapeutics.
[26] J. Schellens,et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.
[27] H. Rosing,et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.